by Truveta Research | Nov 10, 2023 | Research, Research Insights
Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023. A potential side effect of the drug is brain swelling and/or small hemorrhages and is most common for people with the APOE ε4 genetic variant, therefore rates of APOE e4...
by Truveta Staff | Jun 15, 2023 | Technology
We are entering a new era of Alzheimer’s Disease research. Researchers from the University of Tsukuba in Japan along with IBM Research have recently developed a mobile app to detect Alzheimer’s using speech data. New research suggests deep brain stimulation while...
